跳至主要内容
临床试验/NCT01436825
NCT01436825已完成不适用

A Validation Study of the OPTIMS Pharmacokinetic Calculator for Clinician Use in Prophylactic Treatment of Patients With Haemophilia A.

Bayer0 个研究点目标入组 69 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
69
主要终点
The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool

研究概览

简要总结

OPTIMS is a non interventional validation study of the calculator developed by Bayer for clinician's use in the prophylactic treatment by factor VIII of patients with severe or moderate Haemophilia A with a severe clinical profile.

The study takes place during a single visit, at the time of patient enrollment in the study

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient with severe haemophilia A defined as residual factor VIII activity < 1%
  • or Patient with moderate haemophilia A (residual factor VIII activity >1% and <5%) with severe clinical profile
  • Patient treated in prevention with the same plasma or recombinant factor VIII for at least 6 months
  • Patient whose inclusion visit is performed during a routine visit including a measurement of plasma residual factor VIII :c level
  • In the medical file (retrospective data) the pharmacokinetic parameters are available and have been obtained from a PK analysis of factor VIII level performed with the same anti haemophilic factor than the one used on the inclusion day

排除标准

  • Patients with haemophilia B

研究组 & 干预措施

Group 1

干预措施: Recombinant Factor VIII (Kogenate FS, BAY14-2222) (Drug)

结局指标

主要结局

The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool

时间窗: after 1 month

The difference of the elimination half-life calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool

时间窗: after 1 month

The difference of the clearance calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool

时间窗: after 1 month

次要结局

  • The dosage of factor VIII calculated by OPTIMS calculator(within 48 hours after enrollment)
  • The practicality of the OPTIMS calculator by a physician's satisfaction questionnaire(within 48 hours after enrollment)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

已完成
不适用
Observational study to evaluate pharmacokinetics and pharmacodynamics of docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, and capecitabine in elderly patients.cancer malignancies10027655
NL-OMON47924Antoni van Leeuwenhoek Ziekenhuis337
进行中(未招募)
不适用
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disorders
EUCTR2012-000792-16-HUOCTAPHARMA AG23
进行中(未招募)
不适用
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disorders
EUCTR2012-000792-16-CZOCTAPHARMA AG23
进行中(未招募)
不适用
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseases
EUCTR2012-000792-16-DEOCTAPHARMA AG23
招募中
不适用
Validation of Pharmacokinetic and Pharmacodynamic Assays for determination of Nivolumab and Pembrolizumab concentrations, and the occupancy of their target receptor Programmed Death-1 (PD-1) on T-cellsmetastasized cancerSolid tumors10027476
NL-OMON47401Antoni van Leeuwenhoek Ziekenhuis70